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Abstract
Objective: To determine the prevalence and the characteristics of Mycoplasma pneumoniae-related community-
acquired pneumonia (CAP) and parapneumonic pleural effusion (PPE) in children and adolescents. Methods: This 
was a retrospective observational study involving 121 patients with CAP/PPE hospitalized in a tertiary referral 
hospital between 2000 and 2008, divided into six groups according to the etiologic agent (G1 to G6, respectively): 
M. pneumoniae with or without co-infection, in 44 patients (group 1); etiologic agents other than M. pneumoniae, 
in 77 (group 2); M. pneumoniae without co-infection, in 34 (group 3); Streptococcus pneumoniae, in 36 (group 
4); Staphylococcus aureus, in 31 (group 5); and M. pneumoniae/S. pneumoniae co-infection, in 9 (group 6). 
Results: In comparison with group 2, group 1 showed higher frequencies of females, dry cough, and previous 
use of beta-lactam antibiotics; longer duration of symptoms prior to admission; and lower frequencies of use 
of mechanical ventilation and chest tube drainage. In comparison with groups 4 and 5, group 3 showed higher 
frequencies of previous use of beta-lactam antibiotics and dry cough; longer duration of symptoms prior to 
admission; a lower frequency of use of chest tube drainage; a higher mean age and a lower frequency of 
nausea/vomiting (versus group 4 only); and a lower frequency of use of mechanical ventilation (versus group 
5 only). M. pneumoniae/S. pneumoniae co-infection increased the duration of symptoms prior to admission. 
Conclusions: In this sample, the prevalence of M. pneumoniae-related CAP/PPE was 12.75%. Although the 
disease was milder than that caused by other microorganisms, its course was longer. Our data suggest that 
M. pneumoniae-related CAP/PPE in children and adolescents should be more thoroughly investigated in Brazil.
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Resumo
Objetivo: Determinar a prevalência e as características da pneumonia adquirida na comunidade (PAC) e derrames 
pleurais parapneumônicos (DPP) relacionados a Mycoplasma pneumoniae em um grupo de crianças e adolescentes. 
Métodos: Estudo observacional retrospectivo com 121 pacientes hospitalizados com PAC e DPP em um hospital 
de referência terciária, entre 2000 e 2008, divididos em seis grupos (G1 a G6) segundo o agente etiológico: 
M. pneumoniae com ou sem coinfecção, em 44 pacientes; outros agentes que não M. pneumoniae, em 77; 
M. pneumoniae sem coinfecção, em 34; Streptococcus pneumoniae, em 36; Staphylococcus aureus, em 31; e 
coinfecção M. pneumoniae/S. pneumoniae, em 9, respectivamente. Resultados: Na comparação entre os grupos, 
G1 apresentou frequências maiores em gênero feminino, tosse seca, uso prévio de beta-lactâmicos e na duração 
dos sintomas até a admissão, assim como menor uso de assistência ventilatória e de drenagem torácica que 
G2, enquanto G3 teve maiores frequências em uso prévio de beta-lactâmicos e tosse seca, maior duração dos 
sintomas antes da admissão e menor frequência de uso de drenos torácicos que G4 e G5, ao passo que G3 teve 
média de idade maior e menor frequência de náuseas/vômitos que G4, assim como menor uso de assistência 
ventilatória que G5. A coinfecção M. pneumoniae/S. pneumoniae aumentou a duração dos sintomas até a 
admissão. Conclusões: Nesta amostra, a prevalência de PAC e DPP por M. pneumoniae foi de 12,75%. Embora 
a doença apresentasse quadros mais leves que aquela por outros organismos, a evolução foi mais prolongada. 
Nossos dados sugerem a necessidade de uma maior diligência na investigação de M. pneumoniae em crianças 
e adolescentes com PAC e DPP em nosso meio.
Descritores: Derrame pleural; Empiema pleural; Pneumonia; Mycoplasma pneumoniae.
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cystic fibrosis, or tuberculosis, as well as those 
whose data were incomplete.
During the study period, we included all of 
the HINSG inpatients aged 3 months to 16 years 
with clinical and radiological diagnosis of CAP/
PPE (routine posteroanterior, lateral, and lateral 
decubitus chest X-rays). We included only those 
patients in whom the etiologic agents were found 
to be typical bacteria or M. pneumonia and in 
whom no other atypical bacteria were isolated 
and identified as being the sole etiologic agents.
The diagnosis of M. pneumoniae-related 
pneumonia was based on the finding of 
M. pneumoniae-positive IgM in peripheral blood 
by ELISA. The kit used (ImmunoWELL; GenBio, 
San Diego, CA, USA) has a specificity of 90% and 
a sensitivity of 92% (IgM in the acute phase), 
when compared with PCR.(10) The diagnosis of 
pneumonia due to typical bacteria was based 
on positive blood culture results or isolation of 
the pathogens from pleural fluid.
Between 2000 and 2008, 496 patients 
with CAP/PPE were admitted to the HINSG. 
After having applied the exclusion criteria, we 
initially evaluated 345 children and adolescents 
hospitalized for CAP/PPE; of those, 121 were 
included in the study on the basis of the etiologic 
agent, which was identified as typical bacteria or 
M. pneumonia, no other atypical bacteria having 
been isolated and identified as the sole etiologic 
agents (Figure 1). The patients were divided into 
six groups according to the diagnosis:
•	group	1—M. pneumoniae-related CAP/PPE 
with or without co-infection with other 
etiologic agents
•	group	2—CAP/PPE	due	to	etiologic	agents	
other than M. pneumoniae
•	group	3—M. pneumoniae-related CAP/PPE 
without co-infection
•	group	4—Streptococcus pneumoniae-related 
CAP/PPE
•	group	5—Staphylococcus aureus-related 
CAP/PPE
•	group	 6—	 CAP/PPE	 due	 to	
M. pneumoniae/S. pneumoniae co-infection
Patient data were encoded and entered into 
2007 Microsoft Office Excel spreadsheets, having 
been analyzed with the Epi Info software, version 
6.0. We used the chi-square test and Fisher’s 
exact test in order to evaluate categorical and 
ordinal variables, as well as using ORs in order 
to evaluate the magnitude of the associations. 
Introduction
In Brazil, the prevalence of 
Mycoplasma pneumoniae as the etiologic agent 
of parapneumonic pleural effusion (PPE) remains 
unknown. This is due to the difficulty in correlating 
M. pneumoniae with clinical characteristics; to 
the fact that M. pneumoniae grows little in 
culture media; and to the lack of rapid, specific 
tests in the early phase of community-acquired 
pneumonia (CAP) with PPE.(1)
The clinical presentation of M. pneumoniae 
infection varies widely. The clinical course is 
generally moderate and self-limiting,(2-4) and 
pneumonia occurs in 3-10% of patients. However, 
severe cases of pneumonia have been described, 
PPE having been reported in 4-20%; although 
PPE is generally small and unilateral (on the side 
of the pulmonary infiltrate), it can be massive 
and bilateral.(5-7)
The importance of investigating 
M. pneumoniae-related CAP/PPE (with or 
without co-infection) lies in the fact that the 
microorganism does not respond to the antibiotics 
that are typically used in the treatment of CAP/
PPE, among which are beta-lactam antibiotics.
(8,9) Appropriate treatment prevents prolonged 
clinical manifestations and pulmonary sequelae.(6)
The objective of the present study was to 
compare the characteristics of M. pneumoniae-
related PPE with those of PPE related to other 
etiologic agents in a group of children and 
adolescents treated at a regional referral center 
in Brazil.
Methods
This was a retrospective observational study 
involving 121 children and adolescents with CAP/
PPE hospitalized in the Hospital Infantil Nossa 
Senhora da Glória (HINSG, Nossa Senhora da 
Glória Children’s Hospital), located in the city 
of Vitória, Brazil, between 2000 and 2008. The 
HINSG is a regional tertiary referral teaching 
hospital affiliated with the Espírito Santo State 
Department of Health. The present study was 
approved by the HINSG Research Ethics Committee 
(Protocol no. 34/04).
We excluded patients with neurological 
disease, neuromuscular disease, congenital 
malformation, acquired immunodeficiency, 
congenital heart disease, bronchopulmonary 
dysplasia, neoplasia, bronchiolitis obliterans, 
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and group 2 patients (with other etiologic agents) 
in terms of age. The number of patients younger 
than 5 years of age was found to be 31 (70.5%) 
in group 1 and 64 (83.1%) in group 2. The 
mean age was found to be 4.1 years in group 
1 and 3.1 years in group 2. Regarding gender, 
27 (61.4%) of the patients in group 1 were 
female, as were 32 (41.6%) of those in group 
2, the difference being statistically significant 
(p = 0.03). Previous use of beta-lactam antibiotics 
and the need for being transferred to our facility 
because of treatment failure were more common 
in group 1 (p < 0.01 for both). In comparison 
with group 2, group 1 showed longer duration of 
symptoms prior to admission, higher frequency 
of dry cough, and lower frequency of nausea 
or vomiting (p < 0.01; p < 0.01; and p = 0.03, 
respectively). In contrast, the use of mechanical 
ventilation and chest tube drainage during 
hospitalization was more common in group 2 
(p = 0.03 and p < 0.01, respectively). Deaths 
In addition, we used the Student’s t-test in order 
to compare continuous variables and ANOVA in 
order to compare more than two continuous 
variables. Descriptive statistical analysis results 
are presented as means, medians, and standard 
deviations. For all tests, the level of significance 
required in order to reject the null hypothesis 
was set at 5% (p < 0.05).
Results
Of the 345 HINSG inpatients diagnosed 
with CAP/PPE, M. pneumoniae was found in 
44 (12.75%). The final analysis of the clinical, 
radiological, and hematological profiles of 
the children and adolescents with PPE due to 
M. pneumoniae (44 patients) or other agents 
(77 patients) was performed by comparing the 
six groups.
We found no statistically significant differences 
between group 1 patients (with M. pneumoniae) 
Figure 1 - Flowchart of inclusions, losses, and exclusions among the study population. Study comparing 
patients with community-acquired pneumonia (CAP) and parapneumonic pleural effusion (PPE) due to 
Mycoplasma pneumoniae with those with CAP and PPE due to other etiologic agents. HINSG: Hospital 
Infantil Nossa Senhora da Glória (Nossa Senhora da Glória Children’s Hospital).
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statistically insignificant (p = 0.86). Previous use 
of beta-lactam antibiotics prior to hospitalization 
and the need for being transferred to our facility 
because of treatment failure were significantly 
more common in group 3 (p < 0.01 for both). 
In addition, group 3 showed significantly longer 
duration of symptoms prior to admission and 
higher frequency of dry cough (p = 0.04 and 
p = 0.01, respectively). The use of mechanical 
ventilation during hospitalization was more 
common in group 5, and blood workup showed a 
larger quantity (over 5%) of immature neutrophils 
in that group (p = 0.04 and p < 0.01, respectively). 
We found no significant differences between the 
two groups in terms of C-reactive protein levels. 
Closed chest tube drainage was performed more 
frequently in group 5 (p < 0.01). Although open 
chest tube drainage was also more common in 
that group, the difference was not statistically 
significant. Although there were no significant 
differences between the two groups in terms 
of the frequency of chest X-ray changes, liver 
abscess was more common in group 5 (p = 0.02; 
Table 3).
When we compared the patients in group 6 
(M. pneumoniae/S. pneumoniae co-infection) with 
those in group 4, we found that the mean age was 
3.0 years in the former and 2.5 years in the latter, 
the difference being statistically insignificant. We 
also found that M. pneumoniae/S. pneumoniae 
co-infection prolonged the duration of symptoms 
prior to admission, the mean duration being 
17 days in group 6 and 6 days in group 4 
(p = 0.01; Table 4).
Discussion
In our study sample, M. pneumoniae was found 
in 12.75% of the cases, similar proportions having 
been reported in the literature. In a study published 
in 2006 and involving 81 children with pleural 
effusion, Shen et al.(11) found S. pneumoniae, 
M. pneumoniae, Pseudomonas aeruginosa, 
S. aureus, Haemophilus influenzae, and other 
etiologic agents in 20%, 18%, 10%, 3%, 3%, and 
6% of the cases, respectively. In an 11-year review 
published in 2006 in Spain, Deiros Bronte et al.
(12) found 130 patients younger than 15 years 
of age with PPE, the etiologic agent having 
been documented in 42 (32.3%). Among those 
agents, the most common was S. pneumoniae 
(found in 42.8% of the patients), followed by 
M. pneumoniae (in 19%), S. aureus (in 9.5%), 
occurred only in group 2, 5 patients having 
died. Regarding ancillary tests, blood workup 
showed a predominance of immature neutrophils 
in group 2 (p < 0.01). In contrast, there were no 
statistically significant differences between the 
two groups in terms of C-reactive protein levels 
or biochemical parameters of pleural fluid. The 
chest X-ray finding of minimal pleural effusion 
(PPE < 10 mm) was more common in group 1 
(p = 0.02; Table 1). In 12 of the patients in group 
1, we found co-infection with other bacteria, 
the most common being S. pneumoniae, in 9 
patients (20.5%). In group 2, S. pneumoniae 
was the most common etiologic agent, having 
been found in 36 patients (46.8%), followed by 
S. aureus, in 31 (40.3%; Table 2).
When we compared the patients in group 
3 (M. pneumoniae without co-infection) with 
those in group 2, we found that the removal of 
the 10 cases of co-infection with typical bacteria 
from group 1 had virtually no impact on the 
variables that showed statistically significant 
differences (Table 1).
When we compared the patients in group 
3 with those in group 4 (S. pneumoniae), we 
found that the mean age was 4.25 years in the 
former and 2.58 years in the latter (p = 0.01). 
Previous use of beta-lactam antibiotics prior to 
hospitalization and the need for being transferred 
to our facility because of treatment failure were 
more common in group 3 (p < 0.01 for both). In 
comparison with group 4, group 3 showed longer 
duration of symptoms prior to admission, higher 
frequency of dry cough, and lower frequency 
of nausea or vomiting (p = 0.02; p = 0.01; 
and p < 0.01, respectively). Leukocytosis was 
more common in group 3 (p = 0.01), whereas 
immature neutrophils were more common in 
group 4 (p < 0.01). There were no significant 
differences between the two groups in terms 
of C-reactive protein levels. Closed chest tube 
drainage was performed more frequently in 
group 4 (p < 0.01). Although open chest tube 
drainage was also more common in that group, 
the difference was not statistically significant. 
We found no statistically significant differences 
between the two groups in terms of radiological 
and extrapulmonary changes (Table 3).
When we compared the patients in group 
3 with those in group 5 (S. aureus), we found 
that the mean age was 4.25 years in the former 
and 4.08 years in the latter, the difference being 
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Table 1 - Comparison between the group of patients with Mycoplasma pneumoniae-related community-
acquired pneumonia (CAP) and parapneumonic pleural effusion (PPE) with or without co-infection and the 
group of patients with CAP and PPE due to other etiologic agents.a
Variables Groups pb pc
G1 G2 G3
n = 44 n = 77 n = 34
Age, monthsd 49 ± 42  
(34;8-198)
37 ± 41 
(19;0-203)
51 ± 45  
(33;11-198)
0.1370*** 0.1122***
< 5 years 31 (70.5) 64 (83.1) 24 (70.6) 0.1028* 0.1332*
Female gender 27 (61.4) 32 (26.4) 21 (61.8) 0.0360* 0.0494*
Previous use of beta-lactam 
antibiotics
15 (34.1) 17 (22.1) 13 (38.2) 0.0000* 0.0003*
Treatment failure in another 
hospital
11 (25.0) 12 (15.6) 10 (29.4) 0.0001* 0.0007*
Duration of symptoms, daysd 10 ± 10  
(7;2-60)
6 ± 5  
(6;1-30)
9 ± 7  
(7;2-30)
0.0123**** 0.0577****
>7 days 22 (50.0) 58 (24.7) 16 (47.1) 0.0046* 0.0035*
Signs and symptoms
Dyspnea 39 (88.6) 70 (90.9) 29 (85.3) 0.4564** 0.2847**
Dry cough 24 (54.5) 16 (20.8) 19 (55.9) 0.0011* 0.0013*
Fever ≥ 39°C 17 (38.6) 35 (45.5) 12 (35.3) 0.3403* 0.2169*
Loss of appetite 14 (31.8) 21 (27.3) 10 (29.4) 0.5957* 0.8168*
Chest pain 10 (22.7) 9 (11.7) 7 (20.6) 0.1083* 0.1733**
Abdominal pain 9 (20.5) 27 (35.1) 6 (17.6) 0.9008* 0.0642*
Nausea/vomiting 8 (18.2) 28 (36.4) 4 (11.8) 0.0353* 0.0083**
Rhinorrhea 8 (18.2) 20 (26.0) 6 (17.6) 0.3282* 0.3396*
Diarrhea 7 (15.9) 5 (6.5) 4 (11.8) 0.0902** 0.2787**
Length of hospital stay, daysd 22 ± 15  
(21;6-88)
22 ± 14  
(18;5-91)
19 ± 10  
(15;6-46)
0.9231*** 0.2490*
Use of MV 6 (13.6) 24 (31.2) 4 (11.8) 0.0316* 0.0300*
Use of CTD 32 (72.7) 72 (93.5) 23 (67.6) 0.0015* 0.0007**
Death 0 (0.0) 5 (6.5) 0 (0.0) 0.0993** 0.1541**
Initial blood workup
Hemoglobin ≤ 11 g/dL 36 (81.8) 69 (89.6) 27 (79.4) 0.2235* 0.1267**
Leukocytes ≥ 12,000/mm3 30 (68.2) 43 (55.8) 25 (73.5) 0.1820* 0.0778*
Neutrophils ≥ 8,000/mm3 29 (65.9) 48 (62.3) 24 (70.6) 0.6944* 0.4012*
Immature neutrophils ≥ 5% 27 (61.4) 68 (88.3) 18 (52.9) 0.0005* < 0.0001*
C-reactive proteind 127 ± 140 
(67;7-467)
85 ± 64  
(62;13-282)
138 ± 149  
(67;7-468)
0.5137**** 0.3998****
Pleural fluid 23 (52.3) 58 (75.3) 16 (47.1) 0.0095* 0.0035*
pH < 7.2 5 (26.3) 13 (24.5) 4 (28.6) 0.5512** 0.5005**
Glucose ≤ 40 mg/dL 14 (63.6) 35 (61.4) 8 (53.3) 0.8545* 0.5706*
Proteins > 3.4 g/dL 13 (61.9) 42 (76.4) 9 (60.0) 0.2074* 0.1736**
Leukocytes ≥ 1,000/mm3 16 (69.6) 43 (75.4) 10 (62.5) 0.5889* 0.2355**
Predominance of neutrophils 16 (72.7) 45 (78.9) 11 (73.3) 0.5546* 0.4386**
Procedure
Closed CTD 32 (72.7) 72 (93.5) 23 (67.6) 0.0015** 0.0007**
Closed CTD + open CTD 5 (11.4) 9 (11.7) 1 (2.9) 0.9571* 0.1277**
Closed CTD + decortication 2 (4.5) 2 (2.6) 1 (2.9) 0.4618** 0.6702**
Radiological findings
Minimal pleural effusion 6 (13.6) 2 (2.6) 5 (14.7) 0.0264** 0.0271**
Pneumatoceles 7 (15.9) 10 (13.0) 5 (14.7) 0.6563* 0.5108**
Pneumothorax 7 (15.9) 12 (15.5) 5 (14.7) 0.9623* 0.9056*
Pneumomediastinum 0 (0.0) 1 (1.3) 0 (0.0) 0.6363** 0.6936**
Lung abscess 2 (4.5) 4 (5.2) 1 (2.9) 0.6209** 0.5131**
G1: patients with M. pneumoniae-related CAP and PPE with or without co-infection; G2: patients with CAP and PPE 
due to other etiologic agents; G3: patients with M. pneumoniae-related CAP and PPE without co-infection; MV: 
mechanical ventilation; and CTD: chest tube drainage. aValues expressed as n (%), except where otherwise indicated. 
bComparison between G1 and G2. cComparison between G2 and G3. dValues expressed as mean ± SD (median;range). 
*Chi-square test. **Fisher’s exact test. ***Student’s t-test. ****Kruskal-Wallis test.
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were identified. This would have increased, first 
and foremost, the positivity for S. pneumoniae. 
In childhood pneumonia, S. pneumoniae is 
the most common bacterial agent and rarely 
causes bacteremia, positive blood culture for 
S. pneumoniae being found in < 5% of cases.(16)
When we evaluated the clinical characteristics of 
the patients under study, we found that the mean 
age was higher in group 1 (M. pneumoniae) than 
in group 2 (other etiologic agents), i.e., 4.1 years 
vs. 3.1 years. Age is an important predictor of 
the etiologic agent in CAP.(17) According to the 
British Thoracic Society,(13) bacterial pneumonia 
is more common in children over 3 years of age; 
viral pneumonia is more common in younger 
children; and M. pneumoniae-related pneumonia is 
more common in school-age children. In Finland, 
among children hospitalized for pneumonia, 
the mean age of those infected with typical 
bacteria, M. pneumonia, and virus was found to 
be 39.5 months, 60.2 months, and 18.5 months, 
respectively.(18)
Although M. pneumoniae infection is more 
common in patients in the 5-25 year age bracket, 
it can affect patients of all ages. Waris et al.(4) 
reported that 21% of patients with M. pneumoniae-
related pneumonia were younger than 5 years of 
age. Although M. pneumoniae-related pneumonia 
is less common in patients in that age bracket, 
the clinical profile tends to be more severe, the 
number of hospitalizations being highest among 
Streptococcus pyogenes (in 7.1%), H. influenzae 
(in 7.1%), Mycobacterium tuberculosis (in 4.8%), 
Klebsiella pneumoniae (in 2.3%), mixed anaerobic 
flora (in 2.3%), Coxiella burnetii (in 2.3%), and 
Chlamydophila pneumoniae (in 2.3%).
Pleural effusions constitute a complication of 
pneumonia in children and adolescents, leading to 
increased morbidity and mortality.(13) Despite the 
introduction of vaccination against S. pneumoniae, 
the incidence of PPE has increased fivefold in 
the pediatric population.(14) The causes of this 
increase are unknown, meaning that PPE was not 
caused by S. pneumoniae or S. aureus, and PPE 
cultures were negative for other microorganisms.
(15) Therefore, it is important to understand 
the role of atypical microorganisms, such as 
M. pneumoniae, in CAP/PPE.
One limitation of the present study was that 
typical bacteria were identified by blood and 
pleural fluid culture, the sensitivity of which is far 
lower than is that of ELISA, which was used for 
the diagnosis of M. pneumonia. The sensitivity of 
cultures is commonly low, principally in patients 
who are under treatment with antimicrobial agents. 
In CAP, the sensitivity of blood culture has been 
reported to be lower than 10%, whereas in CAP/
PPE the sensitivity of pleural fluid culture has 
been reported to be approximately 9%.(16) Had 
we used other diagnostic methods, we would 
probably have detected microorganisms in several 
of the 223 patients in whom no etiologic agents 
Table 2 - Comparison between the group of patients with community-acquired pneumonia (CAP) and 
parapneumonic pleural effusion (PPE) due to Mycoplasma pneumoniae and another microorganism and 
the group of patients with CAP and PPE due to etiologic agents other than M. pneumoniae in terms of the 
bacteria identified.
Variables Groups
G1 G2
n = 44 n = 77
n % n %
With typical bacteria 10 22.8 77 100
Streptococcus pneumoniae 9 20.5 36 46.8
Streptococcus pyogenes 0 0.0 3 3.9
Other streptococci 0 0.0 2 2.6
Staphylococcus aureus 1 2.3 31 40.3
Staphylococcus epidermidis 0 0.0 1 1.3
Klebsiella pneumoniae 0 0.0 3 3.9
Haemophilus influenzae 0 0.0 1 1.3
With atypical bacteria 2 4.6 0 0.0
Chlamydia sp. 2 4.6 0 0.0
G1: patients with CAP and PPE due to M. pneumoniae with co-infection; and G2: patients with CAP and PPE due to 
other etiologic agents.
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Table 3 - Comparison among the group of patients with community-acquired pneumonia (CAP) and 
parapneumonic pleural effusion (PPE) due to Mycoplasma pneumoniae without co-infection, the group 
of patients with CAP and PPE due to Streptococcus pneumoniae, and the group of patients with CAP and 
PPE due to Staphylococcus aureus.
Variables Groups pb pc
G3 G4 G5
n = 34 n = 36 n = 31
Age, monthsd 51 ± 45  
(33;11-198)
32 ± 31  
(19;5-160)
49 ± 54  
(24;0-203)
0.0111**** 0.8684***
< 5 years 24 (70.6) 31 (86.1) 23 (74.2) 0.1136* 0.7456*
Female gender 21 (61.8) 14 (38.9) 15 (48.4) 0.0557* 0.2785*
Previous use of beta-lactam 
antibiotics
13 (38.2) 6 (16.7) 9 (29.0) 0.0021* 0.0014*
Treatment failure in another 
hospital
10 (29.4) 4 (11.1) 5 (16.1) 0.0080* 0.0014*
Duration of symptoms, daysd 9 ± 7 (7;2-30) 6 ± 5 (6;2-30) 6 ± 5 (6;1-30) 0.1823**** 0.0450***
>7 days 16 (47.1) 8 (22.2) 7 (22.6) 0.0286* 0.0392*
Signs and symptoms
Dyspnea 29 (85.3) 35 (97.2) 26 (83.9) 0.0866** 0.5715**
Cough 24 (70.58) 30 (83.3) 14 (45.2) 0.2043* 0.0377*
Dry cough 19 (55.9) 11 (30.6) 4 (12.9) 0.0104* 0.0043*
Fever ≥ 39°C 12 (35.3) 16 (44.4) 14 (45.2) 0.4630* 0.4868*
Loss of appetite 10 (29.4) 10 (27.8) 8 (25.8) 0.8797* 0.7456*
Chest pain 7 (20.6) 4 (11.1) 5 (16.1) 0.2761* 0.6434*
Abdominal pain 6 (17.6) 12 (33.3) 12 (38.7) 0.1334* 0.0580*
Nausea/vomiting 4 (11.8) 17 (47.2) 8 (25.8) 0.0012* 0.1450*
Rhinorrhea 6 (17.6) 11 (30.6) 6 (19.4) 0.2081* 0.8593*
Diarrhea 4 (11.8) 4 (11.1) 0 (0.0) 0.6120** 0.0684**
Length of hospital stay, daysd 19 ± 10  
(15;6-46)
22 ± 18  
(15;5-91)
21 ± 10  
(21;8-50)
0.6506**** 0.2987***
Use of MV 4 (11.8) 9 (25.0) 10 (32.3) 0.1546* 0.0447*
Use of CTD 23 (67.6) 34 (94.4) 30 (96.8) 0.0039* 0.0025*
Death 0 (0.0) 3 (8.3) 2 (6.5) 0.1304** 0.2235**
Initial blood workup
Hemoglobin ≤ 11 g/dL 27 (79.4) 34 (94.4) 25 (80.6) 0.0629* 0.9011*
Leukocytes ≥ 12,000/mm3 25 (73.5) 16 (44.4) 21 (67.7) 0.0135* 0.6083*
Leukocytes < 5,000/mm3 0 (0.0) 8 (22.2) 3 (9.7) 0.0032** 0.1029**
Neutrophils ≥ 8,000/mm3 24 (70.6) 19 (52.8) 23 (74.2) 0.1260* 0.7456*
Immature neutrophils ≥ 5% 18 (52.9) 31 (86.1) 28 (90.3) 0.0024* 0.0009*
C-reactive protein, mg/dLd 138 ± 149  
(67;7-468)
72 ± 47  
(60;47-248)
111 ± 89  
(67;13-282)
0.2493**** 0.6034***
Pleural fluid 16 (47.1) 28 (77.8) 22 (71.0) 0.0078* 0.0507*
pH < 7.2 4 (28.6) 7 (28.0) 5 (22.7) 0.6242** 0.4938**
Glucose ≤ 40 mg/dL 8 (53.3) 19 (67.9) 13 (59.1) 0.3476** 0.7285*
Proteins > 3.4 g/dL 9 (60.0) 22 (78.6) 16 (76.2) 0.1738** 0.2394**
Leukocytes ≥ 1,000/mm3 10 (62.5) 21 (75.0) 17 (77.2) 0.2950** 0.2497**
Predominance of neutrophils 11 (73.3) 18 (64.3) 21 (95.4) 0.4016** 0.0757**
G3: patients with M. pneumoniae-related CAP and PPE without co-infection; G4: patients with Streptococcus pneumoniae-
related CAP and PPE; G5: patients with Staphylococcus aureus-related CAP and PPE; MV: mechanical ventilation; and 
CTD: chest tube drainage. aValues expressed as n (%), except where otherwise indicated. bComparison between G3 and 
G4. cComparison between G3 and G5. dValues expressed as mean ± SD (median;range). *Chi-square test. **Fisher’s exact 
test. ***Student’s t-test. ****Kruskal-Wallis test.
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and S. aureus. M. pneumoniae/S. pneumoniae 
co-infection increased the duration of 
symptoms prior to admission, the mean of 
which was found to be 17 days for those with 
M. pneumoniae/S. pneumoniae co-infection 
and 6 days for those with S. pneumoniae alone. 
Therefore, prolonged PPE should raise the 
hypothesis of M. pneumoniae with or without 
co-infection.
In the present study, the bacterium that 
was most commonly found in association with 
M. pneumoniae was S. pneumoniae, having 
been found in 9 patients (20.5%). It has been 
reported that up to 30% of patients with CAP 
can present with M. pneumoniae/S. pneumoniae 
co-infection.(18)
Among the signs and symptoms, dry cough 
was found to be more common in the group of 
patients with M. pneumoniae, whereas nausea/
vomiting were found to be more common in the 
group of patients with other etiologic agents. 
such patients. In 2004 in Finland, Korppi et al.
(18) found hospitalization rates of 67%, 5%, and 
9% in patients aged < 4 years, 5-9 years, and 
10-14 years, respectively. It is of note that more 
than 70% of the patients with M. pneumonia 
in our study were younger than 5 years of age. 
The abovementioned data underscore the need 
for including M. pneumoniae in the differential 
diagnosis of PPE not only in individuals in the 
5-25 year age bracket but also in those who are 
younger than 5 years of age.
The duration of symptoms prior to admission 
plays an important role in differentiating PPEs. 
In patients with M. pneumoniae, the onset of 
symptoms is generally gradual (i.e., over a period 
of several days), and the symptoms can persist 
for weeks or months.(19) In the present study, the 
duration of symptoms prior to hospitalization 
was found to be longer in the patients with 
M. pneumoniae than in those with other 
etiologic agents, specifically S. pneumoniae 
Variables Groups pb pc
G3 G4 G5
n = 34 n = 36 n = 31
Procedure
Closed CTD 23 (67.6) 34 (94.4) 30 (96.8) 0.0039* 0.0025*
Closed CTD + open CTD 1 (2.9) 5 (13.9) 3 (9.7) 0.1126** 0.2722**
Closed CTD + decortication 1 (2.9) 1 (2.8) 0 (0.0) 0.7391** 0.5230**
Radiological findings
Minimal pleural effusion 5 (14.7) 1 (2.8) 1 (3.2) 0.0866** 0.1207**
Pneumatoceles 5 (14.7) 1 (2.8) 7 (22.6) 0.0866** 0.4137*
Pneumothorax 5 (14.7) 5 (13.9) 7 (22.6) 0.5948** 0.4137*
Pneumomediastinum 0 (0.0) 1 (2.8) 0 (0.0) 0.5142** 1.0000**
Lung abscess 1 (2.9) 1 (2.8) 0 (0.0) 0.7391* 0.5230**
Extrapulmonary changes
Liver abscess 0 (0.0) 0 (0.0) 5 (16.1) 1.0000* 0.0205**
Cellulitis/skin abscess 0 (0.0) 1 (2.8) 3 (9.7) 0.5142** 0.0920**
Septic arthritis 0 (0.0) 1 (2.8) 3 (9.7) 0.5142** 0.1029**
Osteomyelitis 0 (0.0) 0 (0.0) 1 (3.2) 1.0000* 0.4769**
Cardiac abnormalities 5 (14.7) 1 (2.8) 3 (9.7) 0.0866** 0.4083
Neurological changes 2 (5.9) 0 (0.0) 2 (6.5) 0.2322** 0.6575**
Upper airway changes 2 (5.9) 2 (5.6) 2 (6.5) 0.6709** 0.6575**
Treatment
Macrolides 22 (64.7) 10 (27.8) 0 (0.0) 0.0019* < 0.0001*
Beta-lactam antibiotics 32 (94.1) 36 (100.0) 31 (100.0) 0.1902* 0.3903*
G3: patients with M. pneumoniae-related CAP and PPE without co-infection; G4: patients with Streptococcus pneumoniae-
related CAP and PPE; G5: patients with Staphylococcus aureus-related CAP and PPE; MV: mechanical ventilation; and 
CTD: chest tube drainage. aValues expressed as n (%), except where otherwise indicated. bComparison between G3 and 
G4. cComparison between G3 and G5. dValues expressed as mean ± SD (median;range). *Chi-square test. **Fisher’s exact 
test. ***Student’s t-test. ****Kruskal-Wallis test.
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Table 4 - Comparison between the group of patients with community-acquired pneumonia (CAP) and 
parapneumonic pleural effusion (PPE) due to Streptococcus pneumoniae and the group of patients with 
CAP and PPE due to co-infection with Mycoplasma pneumoniae and Streptococcus pneumoniae.
Variables Groups p
G4 G6
n = 36 n = 9
Age, monthsb 32 ± 31 (19;5-160) 36 ± 26 (32;8-80) 0.6937***
< 5 years 31 (86.1) 7 (77.8) 0.4297**
Female gender 14 (38.9) 5 (55.6) 0.2965**
Duration of symptoms, daysb 6 ± 5 (6;2-30) 17 ± 17 (10;4-60) 0.0112****
>7 days 8 (22.2) 6 (66.7) 0.0171**
Signs and symptoms
Dyspnea 35 (97.2) 9 (100) 0.8000**
Cough 30 (97.2) 8 (88.9) 0.5702**
Dry cough 11 (30.6) 5 (55.6) 0.4692*
Fever ≥ 39°C 16 (44.4) 4 (44.4) 0.6480**
Loss of appetite 10 (27.8) 4 (44.4) 0.2801**
Chest pain 4 (11.1) 2 (22.2) 0.3442**
Abdominal pain 12 (33.3) 3 (33.3) 0.6313**
Nausea/vomiting 17 (47.2) 4 (44.4) 0.5899**
Rhinorrhea 11 (30.6) 2 (22.2) 0.4822**
Diarrhea 4 (11.1) 3 (33.3) 0.1306**
Length of hospital stay, daysb 22 ± 18 (15;5-91) 35 ± 24 (30;9-88) 0.0983***
Use of MV 9 (25.0) 2 (22.2) 0.6184**
Use of CTD 34 (94.4) 8 (88.9) 0.4968**
Death 3 (8.3) 0 (0.0) 0.5031**
Initial blood workup
Hemoglobin ≤ 11 g/dL 34 (94.4) 9 (100.0) 0.6363**
Leukocytes ≥ 12,000/mm3 16 (44.4) 4 (44.4) 0.6480**
Leukocytes < 5,000/mm3 8 (22.2) 2 (22.2) 0.6547**
Neutrophils ≥ 8,000/mm3 19 (52.8) 4 (44.4) 0.4698**
Immature neutrophils ≥ 5% 31 (86.1) 8 (88.9) 0.6557**
Pleural fluid 28 (77.8) 6 (66.7) 0.3815**
pH < 7.2 7 (28.0) 1 (25.0) 0.6999**
Glucose ≤ 40 mg/dL 19 (67.9) 5 (83.3) 0.4161**
Proteins > 3.4 g/dL 22 (78.6) 4 (80.0) 0.7180**
Leukocytes ≥ 1,000/mm3 21 (75.0) 5 (83.3) 0.5624**
Predominance of neutrophils 18 (64.3) 4 (66.8) 0.6494**
Procedure
Closed CTD 34 (94.4) 8 (88.9) 0.4968**
Closed CTD + open CTD 5 (13.9) 4 (44.4) 0.0626**
Closed CTD + decortication 1 (2.8) 1 (11.1) 0.3636**
Radiological findings
Pneumatoceles 1 (2.8) 2 (22.2) 0.0972**
Pneumothorax 5 (13.9) 2 (22.2) 0.4297**
Pneumomediastinum 1 (2.8) 0 (0.0) 0.8000**
Lung abscess 1 (2.8) 1 (11.1) 0.3636**
G4: patients with CAP and PPE due to Streptococcus pneumoniae; G6: patients with CAP and PPE due to Mycoplasma pneumoniae 
and S. pneumoniae; MV: mechanical ventilation; and CTD: chest tube drainage. aValues expressed as n (%), except where 
otherwise indicated. bValues expressed as mean ± SD (median;range). *Chi-square test. **Fisher’s exact test. ***Student’s 
t-test. ****Kruskal-Wallis test.
Mycoplasma pneumoniae-related community-acquired pneumonia  
and parapneumonic pleural effusion in children and adolescents
J Bras Pneumol. 2012;38(2):226-236
235
in the group of patients with S. aureus, confirming 
hematogenous dissemination in those cases.
The usual treatment for PPE does not 
include drugs against M. pneumoniae, which 
is naturally resistant to beta-lactam antibiotics 
(such as penicillins, penicillin derivatives, and 
cephalosporins) because it has no cell wall.(23) Beta-
lactam antibiotics were used prior to hospitalization 
in 38.0% of the patients with M. pneumoniae, in 
16.7% of those with S. pneumoniae, and in 29% 
of those with S. aureus. Therefore, the use of 
beta-lactam antibiotics in children with CAP/PPE 
prior to hospitalization, with no improvement in 
the symptoms and with persistent fever, constitutes 
evidence for a differential diagnosis of atypical 
bacteria.
Our data suggest that M. pneumoniae-related 
CAP/PPE in children and adolescents should be 
more thoroughly investigated in Brazil. Prospective 
longitudinal studies should be able to explain 
the role of M. pneumoniae in PPE, principally 
in children younger than 5 years of age, as 
demonstrated in the present study.
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